Glucagon and GLP-1 receptor co-agonist
Survodutide 4.8 mg subcutaneous once weekly
SURV_SC_4p8MG_QW
Related
- All doses pooled: Survodutide injection
- Survodutide 0.3 mg subcutaneous once weekly
- Survodutide 0.9 mg subcutaneous once weekly
- Survodutide 1.8 mg subcutaneous once weekly
- Survodutide 2.7 mg subcutaneous once weekly
- Survodutide 1.2 mg injection
- Survodutide 1.8 mg injection
- Survodutide 6.0 mg subcutaneous once weekly
- Survodutide 0.6 mg subcutaneous once weekly
- Survodutide 2.4 mg subcutaneous once weekly
- Survodutide 3.6 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -11.74 (-16.24 to -6.45) | 0.68 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 9.71 (1.87 to 37.76) | 0.72 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 12.58 (2.49 to 38.93) | 0.72 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 13.46 (3.35 to 48.39) | 0.80 |